We are committed to serving the best interests of our shareholders.

Filter Releases
 
Press Releases
Date Title and Summary View
8/08/2017 ZEJULA is the most prescribed PARP inhibitor in U.S.; Q2 net sales totaled $26 million in first quarter of availabilityRecently opened European niraparib EAP has enrolled 200 patientsVARUBY oral launch now underway in Europe Dose-escalation o...
7/27/2017 — Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia — TESARO to Receive $100...
7/25/2017 WALTHAM, Mass., July 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its second-quarter 2017 financial results on Tuesday, August 8, 2017, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on August 8, 2017 to discuss the Com...
6/29/2017 WALTHAM, Mass., June 29, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Ovarian Cancer Research Fund Alliance (OCRFA) as the Presenting Sponsor of the 2017 Ovarian Cancer National Conference, being held July 7-9 in Chicago, IL. The OCRFA National Con...
6/28/2017 WALTHAM, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to announce Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., President and COO, have been named EY Entrepreneurs of the Year® in Life Sciences Development for the New England program. The awa...
6/26/2017 WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Healthcare Businesswomen's Association (HBA) as a Corporate Partner. HBA is the leading global organization committed to furthering the advancement and impact of women in healthc...
6/07/2017 WALTHAM, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation at the Goldman Sachs 38th Annual Global Healthcare Conference, to be held June 13-15, 2017 at the Terranea Resort in Rancho Palos Verdes, California. Tim Pearson, ...
6/03/2017 Initial TOPACIO data for niraparib plus KEYTRUDA® is indicative of potentially synergistic anti-tumor activity in platinum-resistant ovarian cancerPhase 1 results for TSR-042 show anti-PD-1 activityThree posters presented during ASCO describe additional an...
5/25/2017 Investor briefing to be webcast from Chicago on June 3, 2017 at 6:15 PM CT WALTHAM, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of three ZEJULA™ (niraparib) abstracts at...
5/22/2017 WALTHAM, Mass., May 22, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the results of the ...
Page:
...
Next Last
 
= add release to Briefcase